Attenuation of rate of change in carotid intima-media thickness by lipid-modifying drugs: Impact on clinical outcomes

American Journal of Cardiovascular Drugs

Volumn 11, Issue 4, 2011, Pages 253-263

  Peters, Sanne A E ^a   Den Ruijter, Hester M ^a   Bots, Michiel L ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Antihyperlipidaemics; Atherosclerosis; Cardiovascular disorders; Clinical trial design; Ezetimibe; HMG CoA reductase inhibitors; Lipid modulators; Niacin; Torcetrapib

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; EZETIMIBE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TORCETRAPIB;

ADD ON THERAPY; ARTERIAL WALL THICKNESS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAROTID ARTERY; CAROTID INTIMA MEDIA THICKNESS; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; EVIDENCE BASED MEDICINE; FOLLOW UP; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; META ANALYSIS (TOPIC); MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE;

CAROTID ARTERIES; HUMANS; HYPOLIPIDEMIC AGENTS; META-ANALYSIS AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; TUNICA INTIMA; TUNICA MEDIA;

EID: 79960266635     PISSN: 11753277     EISSN: 1179187X     Source Type: Journal    
DOI: 10.2165/11591960-000000000-00000     Document Type: Review

References (72)

1. World Health Organization. The World Health Report 2008 [online]. Available from URL: http://www who int/whr/en/ [Accessed 2009 Jun 7]
2. Salonen R, Salonen JT. Determinants of carotid intima-media thickness: a population-based ultrasonography study in eastern Finnish men. J Intern Med 1991 Mar; 229 (3): 225-31
3. Bots ML, Hoes AW, Koudstaal PJ, et al. Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study. Circulation 1997 Sep 2; 96 (5): 1432-7 (Pubitemid 27375333)
4. Dijk JM, van der GY, Bots ML, et al. Carotid intima-media thickness and the risk of new vascular events in patients with manifest atherosclerotic disease: the SMART study. Eur Heart J 2006 Aug; 27 (16): 1971-8 (Pubitemid 44297372)
5. OLeary DH, Polak JF, Kronmal RA, et al. Distribution and correlates of sonographically detected carotid artery disease in the Cardiovascular Health Study. The CHS Collaborative Research Group. Stroke 1992 Dec; 23 (12): 1752-60
6. Heiss G, Sharrett AR, Barnes R, et al. Carotid atherosclerosis measured by B-mode ultrasound in populations: associations with cardiovascular risk factors in the ARIC study. Am J Epidemiol 1991 Aug 1; 134 (3): 250-6
7. Lorenz MW, Markus HS, Bots ML, et al. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and metaanalysis. Circulation 2007 Jan 30; 115 (4): 459-67 (Pubitemid 46184197)
8. Bedi US, Singh M, Singh PP, et al. Effects of statins on progression of carotid atherosclerosis as measured by carotid intimal-medial thickness: a metaanalysis of randomized controlled trials. J Cardiovasc Pharmacol Ther 2010 Sep; 15 (3): 268-73
9. Bots ML, Evans GW, Riley WA, et al. Carotid intima-media thickness measurements in intervention studies: design options, progression rates, and sample size considerations. A point of view. Stroke 2003Dec; 34 (12): 2985-94 (Pubitemid 37517782)
10. Crouse III JR, Byington RP, Bond MG, et al. Pravastatin, Lipids, and Atherosclerosis in the CarotidArteries (PLAC-II).AmJ Cardiol 1995Mar 1; 75 (7): 455-9
11. MacMahon S, Sharpe N, Gamble G, et al. Effects of lowering average of below-average cholesterol levels on the progression of carotid atherosclerosis: results of the LIPID Atherosclerosis Substudy. LIPID Trial Research Group. Circulation 1998 May 12; 97 (18): 1784-90 (Pubitemid 28213621)
12. Salonen R, Nyyssonen K, Porkkala E, et al. Kuopio Atherosclerosis Prevention Study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. Circulation 1995 Oct 1; 92 (7): 1758-64
13. Crouse III JR, Raichlen JS, RileyWA, et al. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA 2007 Mar 28; 297 (12): 1344-53
14. Pignoli P, Tremoli E, Poli A, et al. Intimal plus medial thickness of the arterial wall: a direct measurement with ultrasound imaging. Circulation 1986 Dec; 74 (6): 1399-406 (Pubitemid 17189260)
15. Wong M, Edelstein J, Wollman J, et al. Ultrasonic-pathological comparison of the human arterial wall: verification of intima-media thickness. Arterioscler Thromb 1993 Apr; 13 (4): 482-6 (Pubitemid 23107119)
16. Gamble G, Beaumont B, Smith H, et al. B-mode ultrasound images of the carotid artery wall: correlation of ultrasound with histological measurements. Atherosclerosis 1993 Sep; 102 (2): 163-73 (Pubitemid 23283951)
17. Wikstrand J. Methodological considerations of ultrasound measurement of carotid artery intima-media thickness and lumen diameter. Clin Physiol Funct Imaging 2007 Nov; 27 (6): 341-5 (Pubitemid 47604417)
18. Bots ML, de Jong PT, Hofman A, et al. Left, right, near or far wall common carotid intima-media thickness measurements: associations with cardiovascular disease and lower extremity arterial atherosclerosis. J Clin Epidemiol 1997 Jul; 50 (7): 801-7 (Pubitemid 27379790)
19. Furberg CD, Byington RP, Craven TE. Lessons learned from clinical trials with ultrasound end-points. J Intern Med 1994 Nov; 236 (5): 575-80 (Pubitemid 24340017)
20. Iglesias del SolA, Bots ML, Grobbee DE, et al. Carotid intima-media thickness at different sites: relation to incident myocardial infarction. The Rotterdam Study. Eur Heart J 2002 Jun; 23 (12): 934-40 (Pubitemid 35203871)
21. Chambless LE, Heiss G, Folsom AR, et al. Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the Atherosclerosis Risk in Communities (ARIC) study, 1987-1993. Am J Epidemiol 1997 Sep 15; 146 (6): 483-94 (Pubitemid 27391409)
22. Dogan S, Duivenvoorden R, Grobbee ED, et al. Completeness of carotid intima media thickness measurements depends on body composition: the RADIANCE 1 and 2 trials. J Atheroscler Thromb 2010; 17 (5): 526-35
23. Bots ML, Evans GW, Riley W, et al. The Osteoporosis Prevention and Arterial effects of tiboLone (OPAL) study: design and baseline characteristics. Control Clin Trials 2003 Dec; 24 (6): 752-75 (Pubitemid 37521301)
24. Salonen JT, Salonen R. Ultrasound B-mode imaging in observational studies of atherosclerotic progression. Circulation 1993 Mar; 87 (3 Suppl.): II56-65 (Pubitemid 23068573)
25. Chambless LE, Folsom AR, Clegg LX, et al. Carotid wall thickness is predictive of incident clinical stroke: the Atherosclerosis Risk in Communities (ARIC) study. Am J Epidemiol 2000 Mar 1; 151 (5): 478-87 (Pubitemid 30471022)
26. OLeary DH, Polak JF, Kronmal RA, et al. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med 1999 Jan 7; 340 (1): 14-22 (Pubitemid 29024679)
27. Hodis HN, Mack WJ, LaBree L, et al. The role of carotid arterial intima-media thickness in predicting clinical coronary events. Ann Intern Med 1998 Feb 15; 128 (4): 262-9 (Pubitemid 28090756)
28. Held C, Hjemdahl P, Eriksson SV, et al. Prognostic implications of intimamedia thickness and plaques in the carotid and femoral arteries in patients with stable angina pectoris. Eur Heart J 2001 Jan; 22 (1): 62-72 (Pubitemid 32622190)
29. Kitamura A, Iso H, ImanoH, et al. Carotid intima-media thickness and plaque characteristics as a risk factor for stroke in Japanese elderly men. Stroke 2004 Dec; 35 (12): 2788-94 (Pubitemid 39565172)
30. Rosvall M, Janzon L, Berglund G, et al. Incident coronary events and case fatality in relation to common carotid intima-media thickness. J Intern Med 2005 May; 257 (5): 430-7 (Pubitemid 40604547)
31. Rosvall M, Janzon L, BerglundG, et al. Incidence of stroke is related to carotid IMT even in the absence of plaque. Atherosclerosis 2005 Apr; 179 (2): 325-31 (Pubitemid 40364627)
32. Murakami S,OtsukaK,Hotta N, et al.Common carotid intima-media thickness is predictive of all-cause and cardiovascular mortality in elderly community-dwelling people: Longitudinal Investigation for the Longevity and Aging in Hokkaido County (LILAC) study. Biomed Pharmacother 2005 Oct; 59 Suppl. 1: S49-53 (Pubitemid 41594576)
33. Lorenz MW, von KS, Steinmetz H, et al.Carotid intima-media thickening indicates a higher vascular risk across a wide age range: prospective data from the Carotid Atherosclerosis Progression Study (CAPS). Stroke 2006 Jan; 37(1): 87-92 (Pubitemid 43732053)
34. Wang JG, Staessen JA, Li Y, et al. Carotid intima-media thickness and antihypertensive treatment: a meta-analysis of randomized controlled trials. Stroke 2006 Jul; 37 (7): 1933-40 (Pubitemid 44297754)
35. Yokoyama H, Katakami N, Yamasaki Y. Recent advances of intervention to inhibit progression of carotid intima-media thickness in patients with type 2 diabetes mellitus. Stroke 2006 Sep; 37 (9): 2420-7 (Pubitemid 44337193)
36. Hodis HN, Mack WJ, Lobo RA, et al. Estrogen in the prevention of atherosclerosis: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2001 Dec 4; 135 (11): 939-53 (Pubitemid 33131615)
37. Bots ML, Evans GW, Riley W, et al. The effect of tibolone and continuous combined conjugated equine oestrogens plus medroxyprogesterone acetate on progression of carotid intima-media thickness: the Osteoporosis Prevention and Arterial effects of tiboLone (OPAL) study. EurHeart J 2006Mar; 27 (6): 746-55
38. Angerer P, Stork S, Kothny W, et al. Effect of oral postmenopausal hormone replacement on progression of atherosclerosis: a randomized, controlled trial. Arterioscler Thromb Vasc Biol 2001 Feb; 21 (2): 262-8 (Pubitemid 32125376)
39. de Groot E, Zwinderman AH, van der Steen AF, et al. Variance components analysis of carotid and femoral intima-media thickness measurements. REGRESS Study Group, Interuniversity Cardiology Institute of The Netherlands, Utrecht, The Netherlands. Regression Growth Evaluation Statin Study. Ultrasound Med Biol 1998 Jul; 24 (6): 825-32
40. Hodis HN, Mack WJ, LaBree L, et al. Reduction in carotid arterial wall thickness using lovastatin and dietary therapy: a randomized controlled clinical trial. Ann Intern Med 1996 Mar 15; 124 (6): 548-56 (Pubitemid 26085055)
41. Furberg CD, Adams Jr HP, Applegate WB, et al. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Circulation 1994 Oct; 90 (4): 1679-87 (Pubitemid 24320914)
42. Mercuri M, Bond MG, Sirtori CR, et al. Pravastatin reduces carotid intimamedia thickness progression in an asymptomatic hypercholesterolemic Mediterranean population: the Carotid Atherosclerosis Italian Ultrasound Study. Am J Med 1996 Dec; 101 (6): 627-34 (Pubitemid 27150041)
43. Hedblad B, Wikstrand J, Janzon L, et al. Low-dose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness: main results from the Beta-Blocker Cholesterol-Lowering Asymptomatic Plaque Study (BCAPS). Circulation 2001 Apr 3; 103 (13): 1721-6 (Pubitemid 32291407)
44. Beishuizen ED, van de Ree MA, Jukema JW, et al. Two-year statin therapy does not alter the progression of intima-media thickness in patients with type 2 diabetes without manifest cardiovascular disease. Diabetes Care 2004 Dec; 27 (12): 2887-92 (Pubitemid 39565054)
45. Shukla A, Sharma MK, Jain A, et al. Prevention of atherosclerosis progression using atorvastatin in normolipidemic coronary artery disease patients: a controlled randomized trial. Indian Heart J 2005 Nov; 57 (6): 675-80 (Pubitemid 43332288)
46. Anderssen SA, Hjelstuen AK, Hjermann I, et al. Fluvastatin and lifestyle modification for reduction of carotid intima-media thickness and left ventricular mass progression in drug-treated hypertensives. Atherosclerosis 2005 Feb; 178 (2): 387-97 (Pubitemid 40193456)
47. Taylor AJ, Sullenberger LE, Lee HJ, et al. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 2004 Dec 7; 110 (23): 3512-7 (Pubitemid 39612564)
48. Kastelein JJ, van Leuven SI, Burgess L, et al. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med 2007 Apr 19; 356 (16): 1620-30 (Pubitemid 46631671)
49. Bots ML, Visseren FL, Evans GW, et al. Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. Lancet 2007 Jul 14; 370 (9582): 153-60 (Pubitemid 47042895)
50. Kastelein JJ, Akdim F, Stroes ES, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008 Apr 3; 358 (14): 1431-43 (Pubitemid 351482735)
51. Espeland MA, OLeary DH, Terry JG, et al. Carotid intimal-media thickness as a surrogate for cardiovascular disease events in trials of HMG-CoA reductase inhibitors. Curr Control Trials Cardiovasc Med 2005 Mar 10; 6 (1): 3
52. Smilde TJ, van WS, Wollersheim H, et al. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet 2001 Feb 24; 357 (9256): 577-81 (Pubitemid 32179609)
53. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998 May 27; 279 (20): 1615-22 (Pubitemid 28248586)
54. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998 Nov 5; 339 (19): 1349-57
55. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.NEngl J Med 1996 Oct 3; 335 (14): 1001-9 (Pubitemid 26338729)
56. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995 Nov 16; 333 (20): 1301-7
57. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in theCollaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebocontrolled trial. Lancet 2004 Aug 21; 364 (9435): 685-96 (Pubitemid 39140624)
58. Collins R, Armitage J, Parish S, et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003 Jun 14; 361 (9374): 2005-16
59. Deedwania P, Barter P, CarmenaR, et al. Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. Lancet 2006 Sep 9; 368 (9539): 919-28 (Pubitemid 44331360)
60. Pedersen TR, Kjekshus J, Berg K, et al. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) 1994. Atheroscler 2004 Oct Suppl.; 5 (3): 81-7
61. Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lowerthan- average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003 Apr 5; 361 (9364): 1149-58 (Pubitemid 36398384)
62. Serruys PW, de FP, Macaya C, et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA 2002 Jun 26; 287 (24): 3215-22 (Pubitemid 34686102)
63. Ridker PM, Danielson E, Fonseca FA, et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet 2009 Apr 4; 373 (9670): 1175-82
64. Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events.NEngl JMed 2007 Nov 22; 357 (21): 2109-22 (Pubitemid 350146106)
65. RosseboAB, Pedersen TR, BomanK, et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 2008 Sep 25; 359 (13): 1343-56
66. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterollowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005 Oct 8; 366 (9493): 1267-78
67. Mills EJ, Wu P, Chong G, et al. Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170 255 patients from 76 randomized trials. 2011 Feb;104 (2): 109-24
68. Costanzo P, Perrone-Filardi P, Vassallo E, et al. Does carotid intima-media thickness regression predict reduction of cardiovascular events? A metaanalysis of 41 randomized trials. J AmColl Cardiol 2010 Dec 7; 56 (24): 2006-20
69. Goldberger ZD, Valle JA, Dandekar VK, et al. Are changes in carotid intimamedia thickness related to risk of nonfatal myocardial infarction? A critical review and meta-regression analysis. Am Heart J 2010 Oct; 160 (4): 701-14
70. Taylor AJ, Bots ML, Kastelein JJ. Vascular disease: meta-regression of CIMT trials. Data in, garbage out. Nat Rev Cardiol 2011 Mar; 8 (3): 128-30
71. Robinson WS. Ecological correlations and the behavior of individuals. Int J Epidemiol 2009 Apr; 38 (2): 337-41
72. Lorenz MW, Bickel H, Bots ML, et al. Individual progression of carotid intima media thickness as a surrogate for vascular risk (PROG-IMT): rationale and design of a meta-analysis project. Am Heart J 2010 May; 159 (5): 730-6